Business Wire

CORRECTING and REPLACING LOGO NAX Launches as First Platform to Create Corporate Asset-Backed Products, Ventures and Securities

Share

Please replace the logo in the release dated January 13, 2021 with the accompanying corrected logo.

The release reads:

NAX LAUNCHES AS FIRST PLATFORM TO CREATE CORPORATE ASSET-BACKED PRODUCTS, VENTURES AND SECURITIES

  • Company founded by Jeff Schumacher
  • Company already valued at over $300m USD

New Asset Exchange (NAX), a company that brings liquidity to corporate assets, has formally launched today after two and a half years in stealth development. It has established a new model for launching corporate asset-backed products, ventures and securities. NAX is founded by serial entrepreneur Jeff Schumacher.

NAX combines the software and the method to identify, build, launch and scale asset-backed products, ventures and securitized assets for institutional trading. NAX has secured $65m USD to date in investment from 12 institutional, family office and corporate investors across North America, Europe and Asia, valuing the company at over $300m USD. It launches with a global team based in North America and Europe.

NAX has developed software for digital, micro and platform services, as well as cloud commerce that can be utilized to rapidly market test fully compliant products, tradable securities and marketplaces. The firm will be announcing a series of milestones in the coming months to match its ambitious growth plans.

NAX is already working with leading global businesses in multiple industries including energy, healthcare and consumer goods to launch corporate asset-backed products, and is supported by operating partners from global leaders in trading, banking and underwriting to deliver the requisite infrastructure.

NAX CEO and founder Jeff Schumacher, previously founded and scaled BCG Digital Ventures, with the company becoming one of the largest foundries in the world, creating more than 100 businesses and growing to over 1,000 employees in less than six years. He also founded Axon Advisory Partners, before selling it to Booz & Co., creating Booz Digital, which was then acquired by PwC. Schumacher was previously a Partner at McKinsey, and also EVP, CMO and CSO at Sports Authority, a Leonard Green Partners portfolio company.

Jeff Schumacher, CEO and Founder, NAX said: “We are building upon a decade of learnings from working with the world's leading financial exchanges and institutions. With NAX, we are bringing financial innovation across sectors to create value in markets that otherwise would not exist.”

Since its inception, NAX has attracted several high-profile business figures to its Board, including Frank Strauß, former Global CEO of Private and Commercial Banking at Deutsche Bank, and Heiner Leisten, Leisten & Cie. Family Office CEO and previously Senior Partner at BCG, among others.

Frank Strauß, Independent Board Member, NAX said: “In today’s world, financial innovation is the bedrock upon which successful ventures are created. Jeff’s vision for NAX is what attracted me to supporting the company in applying financial innovation to corporate assets and ultimately unlocking significant value from those assets.”

Francisco Arcilla, Partner, TNF Investments, which led the latest NAX fundraising round, said: “As an international investment firm that prides itself on being a catalyst for innovation and industry disruption, we were instantly captivated by NAX and its disruptive approach to asset creation and value generation. We were very excited to lead the latest round of funding for NAX, and we are equally enthusiastic about the prospect of the many ventures and further investment opportunities that NAX will create.“

NAX operates from its headquarters in Manhattan Beach, CA for North America and Paris, France for Europe, with further locations in Palo Alto, New York, London, and Frankfurt. In 2021, it will be expanding to Singapore, Tokyo and Sydney.

About NAX

NAX is a platform to create asset-backed products, ventures and securities for the world's leading institutions. We co-lead the commercialization of these initiatives with our partners.

For more information, visit http://www.naxgrp.com/

Contact information

Vested
Jess Vallance / Matt Jones
nax@fullyvested.com
+447580542069

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Servier announce updated overall survival results of exploratory TASCO1 phase II study of LONSURF ® + bevacizumab in a first-line setting for patients with unresectable mCRC non-eligible for intensive therapy16.1.2021 22:15:00 CETPress release

Servier announced today updated results from the exploratory phase II TASCO1 study evaluating LONSURF® (trifluridine/tipiracil) + bevacizumab and capecitabine + bevacizumab (C-B) in a first-line setting for patients with unresectable metastatic colorectal cancer (mCRC) who are non-eligible for intensive therapy.1 The data were announced today during an oral presentation at the 2021 ASCO Gastrointestinal Cancers Symposium (ASCO-GI). Patients with mCRC who are not eligible for chemotherapy face a large unmet need, with fewer treatment options available to them and lower survival rates. Colorectal cancer (CRC) makes up 9.7% of total global cancer cases, with almost 1.4 million new cases of CRC each year.2 In Europe, CRC is the second most common cause of death due to cancer, and those with a metastatic disease have a 5-year survival rate of just 11%.3 “For patients with metastatic colorectal cancer, those non-eligible for standard combination therapy have few options left and we are conti

H.I.G. Realty Invests in Production Studios & Content Hub in Madrid15.1.2021 09:00:00 CETPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with $43 billion of equity capital under management, announced today that one of its affiliates has invested in Madrid Content City, an approximately 140,000 square meter hub with state of the art audio-visual facilities, including production studios, production & post-production technical facilities, and a university focused on media studies. H.I.G. continues to add to its sizeable portfolio of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Europe Realty Partners, commented: “Madrid Content City will benefit from strong secular tailwinds underpinned by the boom in content production. The state-of-the-art studios and related facilities, the exceptional multinational tenant line-up with long term leases, and its critical mas

Eurofins, the global leader in analytical testing, expands worldwide face mask testing & certification capabilities15.1.2021 07:30:00 CETPress release

Since the start of the pandemic Eurofins (Paris:ERF) has tested thousands of models of surgical and hygienic masks and provided best-in-class speed and certification for PPEs globally, enabling these critical products to get market as fast as possible. Eurofins has developed global leading testing capabilities and certification services in the North America, Europe and Asia ensuring that PPE manufacturers are able to provide the indispensable support needed in the fight against the coronavirus. As of today, Eurofins is one of the few GLP certified and ISO/IEC 17025 accredited laboratory networks to fully cover all testing requirements for surgical/medical and hygienic masks by the FDA, EU regulations and many international and country-specific directives and guidelines such as CEN, CE Marking, ISO, ASTM or OECD. Our robust portfolio for masks includes globally accepted, safety and performance testing, virucidal, bacterial filtration, particle filtration, differential pressure, biocompa

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport ® (abobotulinumtoxinA) in five therapeutic indications15.1.2021 07:00:00 CETPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced results from new analyses of pivotal Phase III clinical trial data to assess treatment intervals over repeat cycles of Dysport® (abobotulinumtoxinA [aboBoNT-A]) in five patient populations. AbobotulinumtoxinA: Evidence for Long Duration of Response from 5 Patient Populations is being shared during the TOXINS 2021 conference, which is taking place virtually between 16-17 January 2020 and is organized by the International Neurotoxin Association.1-28 Ipsen is sharing 26 abstracts during the congress, with data including updates from the recently published surveys into the experience of patients and caregivers, data from the Phase IV ULIS-III trial, and ten abstracts focused on basic science research into neurotoxins.1-27 Spasticity is one of the most common and disabling conditions associated with many neurological conditions in adults and is characterized by velocity-dependent muscle hypertonia. Spasticity can lead to disabilit

Velodyne Lidar Commends NHTSA Plan to Update NCAP14.1.2021 21:58:00 CETPress release

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today commended the U.S. Department of Transportation’s National Highway Traffic Safety Administration (NHTSA) plan to update to its New Car Assessment Program (NCAP). The NHTSA proposal would add four advanced driver assistance system (ADAS) capabilities to the NCAP, keeping pace with evolving safety technologies and providing much-needed information to consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210114005992/en/ Images show vehicle with lidar-based PAEB stopping before adult target @ 50% overlap (above) and vehicle with camera and radar-based PAEB crashing into adult target (below). (Photo: Velodyne Lidar, Inc.) NCAP is the U.S. Government’s premier consumer information program for evaluating vehicle safety performance. The NHTSA proposal to add ADAS technologies to the NCAP includes pedestrian automatic emergency braking, lane keeping support, blind spot warning and

Snow Software Recognized as a 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management14.1.2021 20:39:00 CETPress release

Snow Software, the global leader in technology intelligence, today announced that the company was named a December 2020 Gartner Peer Insights Customers’ Choice for Software Asset Management (SAM) Tools. Gartner defines software asset management tools as technology that “automates many of the tasks required to maintain compliance with software licenses, thereby controlling software spending.” This is the fourth Gartner Peer Insights Customers’ Choice announcement for SAM, and Snow has earned the distinction all four times. Based solely on feedback from verified customers, Gartner Peer Insights Customers’ Choice reflects reviews and ratings published within the last 12 months. Snow received 100 reviews – the most of any vendor in the market – with an overall rating of 4.6 out of 5 as of January 12, 2021. Earlier this year, Snow was recognized as a Leader in Gartner’s 2020 Magic Quadrant for Software Asset Management Tools1 and received the highest scores in three out of four use cases in

Veristat Supported Marketing Applications for 10% of All FDA Novel Drug Approvals in 202014.1.2021 19:15:00 CETPress release

Veristat, a scientific-minded global clinical research organization (CRO), announced today that they supported the marketing applications for 10% of the 2020 US Food and Drug Administration (FDA) novel drug approvals. The FDA approved 53 novel drugs, defined by the FDA as New Molecular Entities (NMEs)i, and Veristat regulatory, statistical, and medical writing experts were integral in preparing five of these NME New Drug Applications. Veristat also prepared NDA/BLAs for three non-NME FDA approvals and one Marketing Authorization Application (MAA) that received approval in Europe. "Despite the global challenges in 2020, Veristat continued to advance its mission of helping clients achieve regulatory approval of novel medical therapies," stated Patrick Flanagan, Chief Executive Officer at Veristat. "Now, more than ever, Veristat is focused on providing expert guidance to facilitate the rapid approval for therapies that improve the lives of patients and their families around the world." Ve

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom